Status:
UNKNOWN
Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Lead Sponsor:
Medical University Innsbruck
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Covid-19
Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan,...
Detailed Description
COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan,...
Eligibility Criteria
Inclusion
- Female and male patients ≥ 18 years.
- Confirmed infection with SARS-CoV-2 according to the definition of the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection
- Signed and dated declaration of consent by the patient according to ICH-GCP Guidelines.
Exclusion
- Female and male patients \< 18 years
- Pregnancy
- Dementia
- Declaration of consent by the patient according to ICH-GCP Guidelines not signed
- Incapacitated patients
Key Trial Info
Start Date :
April 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 28 2022
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04416100
Start Date
April 29 2020
End Date
April 28 2022
Last Update
December 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Innsbruck
Innsbruck, Austria, 6020